Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048185 · ClinicalTrials.gov registry record
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
A clinical trial of Stargardt Disease, sponsored by Nanoscope Therapeutics.
- Active
- Registry status
- 6
- Enrollment target
- 2
- Study locations
NCT06048185: Active study of Stargardt Disease, sponsored by Nanoscope Therapeutics.
NCT06048185 is a study of Stargardt Disease that is active but no longer recruiting, run by Nanoscope Therapeutics. The registered enrollment target is 6 participants, below the 91-participant average among 16 other Stargardt Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06048185, a study of Stargardt Disease, is active but no longer recruiting, sponsored by Nanoscope Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
Primary Outcome
Assessment of incidences, nature, and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs); intraocular inflammation graded through ocular exam; clinical examination, and intraocular pressure.
Conditions Studied
Interventions
- BIOLOGICAL Gene Therapy Product-MCO-010
Study Locations (2)
Florida
- Nanocope Clnical Site - Miami
Texas
- Nanoscope Clinical Site - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2027-07 |
What the registry record for NCT06048185 still lists
NCT06048185 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 91-participant average among 16 other Stargardt Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Gene Therapy Product-MCO-010 is the first listed.
NCT06048185 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06048185 about?
NCT06048185 is a clinical study titled "Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study". The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
What is the current status of trial NCT06048185?
This trial is currently active not recruiting. The enrollment target is 6 participants. The study started on 2023-10-19. Estimated completion is 2027-07.
What conditions does trial NCT06048185 study?
This clinical trial studies the following conditions: Stargardt Disease.
What interventions are being tested in trial NCT06048185?
The interventions under investigation include: Gene Therapy Product-MCO-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06048185?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06048185 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06048185's enrollment target sits among peer trials
6 17th of 16 the lowest of 16 other Stargardt Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI